The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a
direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti‐Xa …

A new generation of antithrombotic agents, which are conventionally known as direct oral
anticoagulants (DOACs), have recently emerged and are continuing to be developed. These …

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

Background Direct oral anticoagulants (DOACs) are the treatment of choice for most patients
with atrial fibrillation and/or noncancer-associated venous thromboembolic disease …

The direct acting oral anticoagulants (DOAC s), including dabigatran, rivaroxaban,
apixaban, and edoxaban, have favorable pharmacokinetic and pharmacodynamic …

Background: The Direct Oral Anticoagulants (DOACs) represent a new generation of
antithrombotic agents, providing direct inhibition of either thrombin (factor IIa; FIIa) or …

Although the direct oral anticoagulants (DOACs) do not require routine monitoring and
reduce bleeding compared with warfarin, there are special circumstances in which …

Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral
anticoagulants Summary One of the key benefits of the direct oral anticoagulants (DOACs) is …

Background There is an increasing amount of literature on direct oral anticoagulant (DOAC)
laboratory monitoring. The aims of the present review were to evaluate published data on …